top of page

Publications and Presentations

WARPNINE Annual Review 2023 Cover.png

WARPNINE Annual Review

Financial Year 2022 -2023

Click here, to download your PDF copy. 

The Lancet .jpg

We are delighted to share the findings, recently published in The Lancet, from the first-in-human study by Dr Andrew Dean, Chair of WARPNINE, and colleagues.

Although early phase, this study showed the best ever result ever seen in a pancreatic cancer trial.


This article was published in The Lancet Gastroenterology & Hepatology, Vol 7, Andrew Dean, Sanjeev Gill, Mark McGregor, Vy Broadbridge, Harri A Järveläinen, Timothy Price, Dual αV-integrin and neuropilin-1 targeting peptide CEND-1 plus nab-paclitaxel and gemcitabine for the treatment of metastatic pancreatic ductal adenocarcinoma: a first-in-human, open-label, multicentre, phase 1 study, Copyright Elsevier Ltd (2022).

bottom of page